Viral Vitalism

Source Library

FDA approves Wegovy to reduce risk of serious heart problems in adults with obesity or overweight and cardiovascular disease

U.S. Food and Drug Administration is tracked in the Viral Vitalism canonical source library.

GovernmentU.S. health regulator
Source type
Government
Access type
Official
Publisher
U.S. Food and Drug Administration
Date
2024-03-08
Added
2026-06-19

Trust profile

94

U.S. health regulator

Publisher type
Regulator
Bias profile
Low

Best used for

  • Approvals
  • Labels
  • Safety communications

Weak for

  • Comparative effectiveness
  • Consumer experience

Used in Viral Vitalism

Claims supported

  • Semaglutide reduced major adverse cardiovascular events in SELECT participants with overweight or obesity and established cardiovascular disease without diabetes.

Related studies

Related sources

Topic tags

glp-1semaglutidewegovycardiovascular-riskobesity

Vital Signals

Get the weekly health signal without the wellness fog.

A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.

No spam. No miracle claims. Just better health signal.

By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.